PET Scans for Decision-Making in Metastatic Renal Cell Carcinoma: A Single-Institution Evaluation

Oncology ◽  
2006 ◽  
Vol 70 (5) ◽  
pp. 339-344 ◽  
Author(s):  
M.S. Dilhuydy ◽  
A. Durieux ◽  
A. Pariente ◽  
H. de Clermont ◽  
G. Pasticier ◽  
...  
Keyword(s):  
Decision Making ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Single Institution ◽  
Pet Scans

scholarly journals EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA: A SINGLE-INSTITUTION STUDY

2018 ◽  
Vol 109 (4) ◽  
pp. 216-219
Author(s):  
Kenichi Harada ◽  
Yusuke Shiraishi ◽  
Kohtaro Suzuki ◽  
Yasuyoshi Okamura ◽  
Yukari Bando ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Efficacy And Safety ◽  
Single Institution

Implications of Therapy Choice on Overall Survival in Metastatic Renal Cell Carcinoma: A Single Institution Experience

2005 ◽  
Vol 22 (4) ◽  
pp. 399-406
Author(s):  
Simrit Parmar ◽  
Alfred W. Rademaker ◽  
Bing B. Fung ◽  
James M. Kozlowski ◽  
Timothy M. Kuzel
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Single Institution ◽  
Therapy Choice

First-line therapy in patients with metastatic renal cell carcinoma (mRCC): Results from consecutive patients over 25 years in a single institution.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16574-e16574
Author(s):  
Niels Fristrup ◽  
Frede Donskov
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Individual Risk ◽  
Single Institution ◽  
First Line ◽  
Treatment Groups ◽  
First Line Therapy ◽  
Line Therapy

e16574 Background: Immune checkpoint inhibitors (ICI) have demonstrated improved activity in metastatic renal cell carcinoma (mRCC). Real-world data comparing the effectiveness of ICI with interleukin-2 (IL-2) is limited. Methods: We retrospectively assessed consecutive patients with biopsy-proven mRCC at our institution between 1994 and 2020. Patients were classified into four groups based on first-line therapy: vascular endothelial growth factor (VEGF) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, IL-2, or ICI. The primary endpoint was overall survival (OS). Kaplan-Meier method was used to compare OS between treatment groups. We used Cox proportional hazards models to adjust for prognostic covariates. Results: A total of 1424 patients were treated with first line therapy; 51% received VEGF, 3% received mTOR, 40% received IL-2, and 6% received ICI. Median follow-up was 97.6 months. Except for the mTOR group, baseline characteristics were largely balanced between the treatment groups. Median OS in the ICI group compared with IL-2, mTOR and VEGF was 40.1, 17.6, 6.3 and 14.7 months (p < 0.001), respectively, and the 5-year survival rate was 36%, 20%, 9% and 14%, respectively. After adjusting for IMDC and MSKCC individual risk factors, histology, age, gender, year of treatment initiation, low sodium, and location of metastases (lung, liver, bone, lymph node), the hazard ratio (HR) (95%CI) for OS with VEGF as reference was 0.50 (0.33-0.74, p = 0.001) for ICI, 0.81 (0.70-0.92, p = 0.002) for IL2, and 1.09 (0.79-1.52, p = 0.6) for mTOR. Conclusions: In this largest single institution cohort to date, patients with mRCC who received CPI achieved longer OS.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document